Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01405885 · ClinicalTrials.gov registry record · Phase 1
A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
NCT01405885: Completed Phase 1 study, sponsored by Inovio Pharmaceuticals.
NCT01405885 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 116 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01405885, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
Study Summary
This is a Phase I, parallel design open label study to evaluate safety, tolerability and immunogenicity of nine different formulation of two individual H1 and one H5 HA plasmid administered intradermally followed by electroporation in healthy adults
Primary Outcome
Frequency and severity of local and systemic reactogenicity signs and symptoms, adverse events and serious adverse events
Interventions
- BIOLOGICAL INO-3605
- BIOLOGICAL INO-3609
- BIOLOGICAL INO-3401
- BIOLOGICAL INO-3605 AND INO-3609
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
What the finished NCT01405885 record still lists
NCT01405885 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% higher).
The record links to 0 conditions, and to 4 interventions - of which INO-3605 is the first listed.
NCT01405885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01405885 about?
NCT01405885 is a clinical study titled "A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus". This is a Phase I, parallel design open label study to evaluate safety, tolerability and immunogenicity of nine different formulation of two individual H1 and one H5 HA plasmid administered intradermally followed by electroporation in healthy adults
What is the current status of trial NCT01405885?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2011-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01405885?
The interventions under investigation include: INO-3605 (BIOLOGICAL), INO-3609 (BIOLOGICAL), INO-3401 (BIOLOGICAL), INO-3605 AND INO-3609 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01405885?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01405885's enrollment target sits among peer trials
116 501st of 2000 higher than 1,497 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia